Related Experiment Video
Updated: Jun 18, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Therapeutic advances in malignant glioma: current status and future prospects
H Ian Robins1, Andrew B Lassman, Deepak Khuntia
1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Abstract:
This article reviews the current status and trends in the treatment of primary gliomas, focusing predominantly on glioblastoma. It also discusses the current standard of care and new targeted agents currently under investigation. Furthermore, the concepts of pseudoprogression and pseudoresponse are introduced, which are new imaging correlates that have significant impact on understanding of the disease.
Insights
This review covers primary glioma and glioblastoma treatments, including standard care and novel targeted agents. It also introduces pseudoprogression and pseudoresponse imaging concepts for better disease understanding.
Area of Science:
- Neuro-oncology
- Oncologic imaging
Background:
- Primary gliomas, particularly glioblastoma, represent a significant challenge in neuro-oncology.
- Current treatment strategies require continuous evolution to improve patient outcomes.
Purpose of the Study:
- To review the current treatment landscape for primary gliomas, with a focus on glioblastoma.
- To discuss emerging targeted therapies and their investigational status.
- To introduce novel imaging concepts like pseudoprogression and pseudoresponse.
Main Methods:
- Literature review of current research and clinical trials in glioma treatment.
- Analysis of standard-of-care protocols and investigational targeted agents.
- Discussion of imaging biomarkers and their clinical implications.
Main Results:
- Glioblastoma treatment remains complex, with ongoing research into novel therapeutic approaches.
- Targeted agents show promise but require further investigation.
- Pseudoprogression and pseudoresponse are critical imaging findings impacting treatment assessment.
Conclusions:
- The management of primary gliomas is evolving, incorporating advanced targeted therapies.
- Understanding imaging correlates like pseudoprogression and pseudoresponse is crucial for accurate disease monitoring and treatment planning.
